An international panel of clinicians, neuroscientists, neuropathologists and neuroimaging specialists has set out what a biomarker for chronic traumatic encephalopathy (CTE) would have to do, and stated that existing markers do not yet do it. The consensus summary from the 2025 Leon Thal Summit, convened at Cleveland Clinic Nevada and published in Alzheimer's & Dementia on 12 May 2026, says the field is held back by the absence of accurate tests that can be applied during life to diagnose, monitor or track the disease. Its central priority is the development of markers that recognise the tau proteoform specific to CTE, while acknowledging that this proteoform may change across disease stages.

CTE is associated with extensive exposure to repetitive head impacts, in contact and collision sports and in military service involving blast exposure. Its defining lesion, seen only under the microscope after death, is a build-up of phosphorylated tau in neurons at the depths of cortical sulci around small blood vessels. Structural differences between CTE tau filaments and those of Alzheimer's disease have been shown by cryo-electron microscopy, and the panel treated that difference as the opening for a specific test. In living people, clinicians instead diagnose traumatic encephalopathy syndrome (TES), the clinical picture defined by National Institute of Neurological Disorders and Stroke consensus research criteria published in Neurology in 2021, which rest on clinical features alone.

The document is an agenda rather than a result, and it is candid about the state of each tool. Tau PET studies, the summary reports, have found small elevations in tracer uptake in regions such as the superior frontal and medial temporal cortices, but not enough to reliably indicate CTE pathology in an individual patient. Plasma p-tau217, a robust marker of amyloid-associated Alzheimer's tau pathology, does not appear to reflect the tau aggregates characteristic of CTE, and is proposed instead as a way to identify coexisting Alzheimer's disease. The panel recommends that currently available markers, including structural MRI findings such as cavum septum pellucidum, Alzheimer's fluid and imaging markers, and longitudinally rising GFAP, be added to the TES research criteria on an exploratory basis only, to test whether they raise the level of diagnostic certainty. It also calls for standardised multi-site MRI acquisition, multimodal panels rather than single measures, and longitudinal clinicopathological studies to provide neuropathological validation.

Charles Bernick, the first author and a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health, has said that fluid, tissue and imaging markers "have rapidly emerged from cohorts of patients in CTE registries", which is the argument for revisiting the question now. The counterpoint sits inside the same document: the summit did not report a validated marker, a threshold or a diagnostic test, and the exploratory additions it proposes are for research cohorts, not for clinics or for families seeking an answer about a living relative.